Q-omics provides the consensus-scored MIR4706 profile across patient tissues and cancer cell-line models. MIR4706 expression is associated with patient survival in 15 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, MIR4706 is differentially expressed in 6, with the highest sampling consensus in BLCA. Additionally, MIR4706 RNA expression shows 6,564 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight ACC, BLCA, and STAD as cancer lineages where MIR4706 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for MIR4706 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes MIR4706 survival associations across molecular data types. MIR4706 RNA expression shows survival associations in the most cancer types (15). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible MIR4706 RNA expression–survival associations across cancer types. High MIR4706 expression shows unfavorable associations in ACC, THCA and DLBC, but favorable associations in LUAD, MESO and SKCM. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for MIR4706 RNA expression.
This table summarizes MIR4706 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in BLCA for RNA.
This table ranks reproducible tumor–normal expression differences for MIR4706. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. MIR4706 shows lower tumor expression in LUAD and higher tumor expression in BLCA, KIRC, LIHC, ESCA and LUSC. The BLCA box plot shows higher MIR4706 RNA expression in tumor versus normal tissue (log2 FC = +0.762, t-test p = .008).
This table shows molecular features associated with MIR4706 in patient tissues and cancer cell lines. In patient samples, MIR4706 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
